Evado to Launch Breakthrough Cloud App at DIA, 06/25/13; Effective for All Sectors; First Available for Healthcare, Clinical Trials
On June 25, 2013, Evado Pty. Ltd. will launch an exciting and innovative new product that promises to streamline clinical trials by allowing the management of information and complex data from a single window/user-interface – regardless of software, format or user device.
Melbourne, Australia (PRWEB) June 20, 2013
Evado, Pty. Ltd., (Evado e-Clinical) an award-winning software company based in Melbourne, Australia, will launch a breakthrough business application (app) at the annual meeting of the Drug Information Association on June 25, in Boston, the company announced today.
The app provides a secure, integrative interface through which users can view, enter, manage and manipulate complex data across multiple platforms on any mobile or desktop computing device– from anywhere, in any language.
Designed for use in all sectors, the app will first be made available to the health care industries–and will be particularly useful in clinical trials.
“Our goal has long been to enhance the delivery of healthcare. We are excited to bring to market an app that will streamline clinical trial processes,” said Jennie Anderson, co-founder of Evado, which has operations in Melbourne, San Francisco and Singapore.
** The launch will take place at the Westin Boston Waterfront Hotel (Adams Room) in Boston at 8:30 AM on Tuesday, June 25, 2013.
** The Evado team will be located in booth 201 in the Boston Convention Center from June 24-26.
Evado is an Australia-based IT company with operations in the US and Asia Pacific. Its customers include research institutes, universities, large and small drug developers and medical device manufacturers–all of whom use Evado for pre-clinical through late stage trials and post-market studies. Evado technologies, employed successfully in numerous GCP and FDA compliant clinical trials and studies, provide significant benefits in cost, setup time, flexibility and visibility to research and commercial clients.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/6/prweb10849549.htm